Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Clinical differentiation through universal response rates at therapeutic dosages creates compelling value propositions for pharmaceutical companies developing next-generation obesity and diabetes treatments
The phase 2 NEJM trial showed NASH resolution in 59% of patients
It is a 47-residue synthetic peptide constructed as a D-retro-inverso (DRI) analog: the primary sequence is reversed and each amino acid is substituted with its D-enantiomer, an arrangement that approximates the topological side-chain presentation of the parent L-peptide while conferring markedly greater resistance to proteolytic degradation in typical aqueous and biological buffer systems used at the bench
The concern is cumulative time outside refrigeration
- mL = 5 / 20 = 0.25 mL - Units = 0.25 x 100 = 25 units Always double-check the concentration on the actual vial before drawing
US$ 28.23
US$ 22.54
US$ 27.05
US$ 21.31
US$ 29.55
US$ 20.38
US$ 21.48
